ResMed, Inc.

Stocks

RMD

US7611521078

Market Closed - NYSE Other stock markets 21:00:02 11/06/2026 BST			5-day change	1st Jan Change
192.39 ^USD	-0.61%		+3.18%	-20.13%

06-09	Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing	MT
06-04	Australian shares fall as Mideast tensions deepen, miners and banks top losers	RE

Transcript : ResMed Inc., Q4 2025 Earnings Call, Jul 31, 2025

Published on 08/01/2025 at 12:01 am BST - Modified on 08/01/2025 at 02:36 am BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Q4 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about ResMed, Inc.

06-09	Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing	MT
06-04	Australian shares fall as Mideast tensions deepen, miners and banks top losers	RE
06-03	ResMed Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 04:40 PM
06-01	ResMed Completes Acquisition of Noctrix Health	MT
06-01	Resmed Closes Acquisition of Noctrix Health	MT
06-01	Australian shares inch lower, hurt by banks and energy; miners limit losses	RE
05-31	ResMed Inc. completed the acquisition of Noctrix Health, Inc.	CI
05-20	ResMed Rises After Partnership With Oura to Expand Sleep Health Education, Care Pathways	MT
05-19	Resmed And OURA Partner To Expand Access To Sleep Health Education And Care	CI
05-18	Apnimed's sleep apnea pill meets main goal in late-stage study	RE
05-11	Resmed Insider Sold Shares Worth $1,037,233, According to a Recent SEC Filing	MT
05-04	CSL, Resmed, Cochlear Lead Losses on ASX	MT
05-02	ResMed: Stock splutters, but machine is still breathing well
05-01	Mizuho Securities Adjusts ResMed Price Target to $235 From $255, Maintains Outperform Rating	MT
05-01	Piper Sandler Adjusts ResMed Price Target to $233 From $275, Maintains Neutral Rating	MT